Safety and E fficacy of Psilocybin for Body Dysmorph ic Disorder  
[STUDY_ID_REMOVED]  
January 10, 2023  
Study Protocol and Statistical Analysis Plan  
Protocol Summary Form
7950
Schneier, Franklin
1
Protocol Title:
Safety and Efficacy of Psilocybin for Body 
Dysmorphic Disorder
Protocol Number:
[ADDRESS_264669] Approval:
02/27/2020
Expi[INVESTIGATOR_5952]:
02/09/2024Version Date:
01/10/2023
Research Area:  
Anxiety, Mood, Eating & Related Disorders
Division:  
Anxiety/PTSD/OCD
Contact [INVESTIGATOR_678]:
[INVESTIGATOR_220283], MD
Email: [EMAIL_4320]
Telephone: 646-774-8041Co-Investigator(s):
David Hellerstein, MD
Research Chief:
Helen Simpson, MD
Cover Sheet
Choose ONE option from the following that is applicable to your study
If you are creating a new protocol, select
 "I am submitting a new protocol." As 5 Year Renewals are 
no longer required, this option remains for historical purposes.
I am submitting an annual continuation without modifications 
Department & Unaffiliated Personnel
Department
What Department does the PI [INVESTIGATOR_40348]?
anxiety-mood-eating and related disorders
Within the department, what Center or group are you
 affiliated with, if any? 
anxiety disorders clinic
Unaffiliated Personnel
List investigators, if any, who will be participating in this protocol but are not affiliated with New 
York State Psychiatric Institute or Columbia University.
 Provide: Full Name, Degrees and Affiliation.
Consultant Jamie Feusner, MD; University of Toronto
Protocol Summary Form
7950
Schneier, Franklin
2
Application for Continuation  of Research
Status
Current Status of Study: 
All research interventions were completed. Only data analysis is ongoing.
Summary of Experiences to Date
Please provide a summary of scientific progress
 of the study and the  experience of research 
participants, to date. This requirement is designed to allow for the investigator and the IRB to 
reassess the study‚Äôs risks and benefits in terms of developments in the field, changing practice 
patterns, and new IRB policies and procedures.
The study has concluded and is in the data analysis stage. Recruitment is closed and subject follow-ups have 
been completed. A total of [ADDRESS_264670] there been any changes in  funding status since the prior approval? 
No
Have the principal investigator [INVESTIGATOR_220284]/product?
Yes
Summary
Have there been any study findings, recent literature, or untoward events occuring here or at other 
sites in the past year which might affect the analysis of the safety, risks or benefits of study 
participation? 
No
Have there been any
 serious adverse events (serious and/or unanticipated problems involving risks to 
subjects or others at this site which occured in the past year)? 
No
Have all study staff with a significant role in the design or implementation of the human subject 
components of this study received required training in human research subject protections?
Yes
Is the study covered by a certificate of confidentiality? 
Yes
Certificate expi[INVESTIGATOR_320] (mm/dd/yyyy) 
12/13/[ADDRESS_264671] there been any significant deviations from the anticipated study recruitment, retention or 
completion estimates? 
No
Comments / additional information 
Sample Demographics
Select the # of samples applicable
Fair
Specify population
White Participants
Total number of participants enrolled from this
 population to date 
8
Specify population #2
Asian Participants
Total number of participants enrolled from this population to date 
3
Specify population #3
Other
Total number of participants enrolled from this population to date 
1
Specify population #4
Female
Total number of participants enrolled from this population to date 
8
Specify population #5
Male
Total number of participants enrolled from this population to date 
4
Gender, Racial and Ethnic Breakdown 
Gender Breakdown 8 female participants 4 male participants Racial Breakdown 8 White participants 3 
Asian Participants 1 participant who identified as other Ethnic Breakdown 1 participant who identified as 
Hispanic/Latino 11 participants who did not identify as Hispanic/Latino
Summary of Current Year's Enrollment and Drop-out  
Number of participants who signed consent in the past year
5
Protocol Summary Form
7950
Schneier, Franklin

Number of participants currently enrolled0Did the investigator withdraw participants from the study? NoDid participants decide to discontinue study involvement? No
3URFHGXUHV
To create the protocol summary form, first indicate if this research will include any of the following procedures 
&ROOHFWLRQRI%LRORJLFDO6SHFLPHQV
,QWHUQHWEDVHG'DWD&ROOHFWLRQRU7UDQVPLVVLRQ
0HGLFDWLRQ7ULDO
05,
3V\FKLDWULF$VVHVVPHQW
8VHRI,QYHVWLJDWLRQDO'UXJRU'HYLFH
3RSXODWLRQ
Indicate which of the following populations will be included in this research
$GXOWV
$GXOWVRYHU
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 15HVHDUFK6XSSRUW)XQGLQJ
This section is to describe the funding sources for your protocol.
If an internal account is to be used, please describe.  The internal account is  
 RFMH  CU
If the project is using, or planning to use, external  funding, provide the details for each external funding 
source.
Compass Pathways
Principal Investigator [INVESTIGATOR_220285]/contract Franklin Schneier
Status of Grant (select one) is currently funded
Source of Funding (select one) Industry 
Institute / Agency N/A
Grant Name [CONTACT_220341] N/A
Sponsor Compass Pathways
Is this research initiated by [CONTACT_093]? Yes
 Site description (select one) Single Site
Business Office (select one) RFMH 
If the grant/contract includes a subcontract, please 
describe.  (To / From, Name [CONTACT_3621](s). Be sure to specify To or From)N/A
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 26WXG\/RFDWLRQ
Indicate if the research is/will be conducted at any of the following:
  NYSPI   Washington Heights Community Service   Other Columbia University Medical Center Facilities
This Protocol describes research conducted by [CONTACT_978] [INVESTIGATOR_220286]/locations:
  Office Of Mental Health Facilities
 Binghamton Psychiatric Center   Bronx Children‚Äôs Psychiatric Center
  Bronx Psychiatric Center   Brooklyn children‚Äôs Psychiatric Center
  Buffalo Psychiatric Center   Capi[INVESTIGATOR_220287]
  Central [LOCATION_001] Psychiatric Center   Creedmoor Psychiatric Center
  Elmira Psychiatric Center   Greater Binghamton Health Center
  Hudson River Psychiatric Center   Hutchings Psychiatric Center
  Kingsboro Psychiatric Center   Kirby [CONTACT_220317]
  Manhattan Psychiatric Center   Middletown Psychiatric Center
  Mid-Hudson Psychiatric Center   Mohawk Valley Psychiatric Center
  Nathan S. Kline Institute   Pi[INVESTIGATOR_220288]
  Queens Children‚Äôs Psychiatric Center   [COMPANY_002]ster Psychiatric Center
  Rockland Children‚Äôs Psyciatric Center   Rockland Psychiatric Center
  Sagamore Children‚Äôs Pyschiatric Center   St. Lawrence Psychiatric Center
  South Beach Psychiatric Center   Western NY Children‚Äôs Psychiatric Center
Or type in location(s)..
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 3Click or tap here to enter text.
  Hospi[INVESTIGATOR_600], clinics and other healthcare facilities
  Bridge Plaza Medical Center
  Harlem Hospi[INVESTIGATOR_307]
  St. Luke‚Äôs-Roosevelt Hospi[INVESTIGATOR_54246]
  Mount Sinai Medical Center
  Weill Cornell Medical Center
Or type in location(s)..
Click or tap here to enter text.
  Schools/Educational Institutions
Type in location(s)..
Click or tap here to enter text.
  Prison System(includes Parole)
Type in location(s)..
Click or tap here to enter text.
  International Sites
Type in location(s)..
Click or tap here to enter text.
  Other Facilities
Type in location(s)..
Click or tap here to enter text.
  Community Sources
Type in location(s)..
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 4Click or tap here to enter text.
/D\6X[COMPANY_003]U\RI3URSRVHG5HVHDUFK
This section is intended to provide a basic overview of the study including a description of its purpose, study procedures, 
and subject population.  The summary should provide a concise overview of the study for non-scientific and scientific members of the IRB.  Please avoid medical or technical term inology.  In general, the abstract of a grant does not provide 
a suitable lay summary.
Body dysmorphic disorder is a common condition charact erized by [CONTACT_220318] "imagined ugliness" with 
debilitating distress, checking and avoidance behaviors, and seeking unnecessary cosmetic medical procedures. Serotonin reuptake inhibitor medications and cognitive behavioral therapy helps some patients, but many do not benefit from existing treatments, and no medications are FDA-approved for this indication. Psilocybin is under development as a treatment of several psychiatric disorders, with placebo-controlled trial evidence of safety and prolonged efficacy for majo r depression when administered as a single dose with 
intensive support by a therapi[INVESTIGATOR_220289]. A single case report in body dysmorphic disorder suggests psilocybin might also have efficacy for this disorder.
In this proposed pi[INVESTIGATOR_799], up to [ADDRESS_264672] of medication on brain circuits.
%DFNJURXQG6LJQLILFDQFHDQG5DWLRQDOH
In this section, provide a brief summary of the status quo of the relevant work field and how the proposed study will 
advance knowledge. Specifically, identify the gaps in knowledge that your project is intended to fill. If no gaps exist that are obviously and directly related to your project, explai n how your proposed research will contribute to the overall 
understanding of your field. Describe potential impacts of your pr oject within your field of study and in a broader context. 
Provide a critical evaluation of existing knowledge. Th e literature review does not have to be exhaustive. 
Significance and Rationale
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 5Body dysmorphic disorder (BDD) is a debilitating psychiatric disorder in which individuals are preoccupi[INVESTIGATOR_220290], causing significant distress and functional impairment (Phillips 2005). Compulsive checking may occur, and sufferers may seek out unnecessary or risky cosmetic procedures. Most co mmon concerns in BDD involve skin, hair, and nose. 
BDD has a high prevalence in the general population of 1.7%-2.9% (Buhlman et al., 2010), but it is under-studied. To date, there have only been controlled clinical  trials to evaluate a single medication class ‚Äì 
serotonin reuptake inhibitors (Phillips et al 2002, 2006;  Hollander et al 1999) ‚Äì and a single psychotherapy 
modality ‚Äì cognitive-behavioral therapy (Wilhelm et al 2014). Although these treatments can be effective in many, they typi[INVESTIGATOR_220291]. There is a need for new intervention approaches.
The rationale for considering psilocybin as a potential treatment for BDD includes a case report (Hanes 2003), 
in which unsupervised use of psilocybin resulted in symptomatic improvement, as well as evidence for psilocybin efficacy in conditions that frequently co-occu r or overlap with BDD, such as obsessive-compulsive 
disorder (Moreno et al, 2006) and major depressive disorder. The first step in further evaluation of the efficacy 
and safety of psilocybin for BDD is this proposed open trial, utilizing methods established in prior controlled trials of psilocybin for other disorders.
Psilocybin Background (see Studerus, et al., 2011, for a useful review)
"Magic mushrooms" have been used ceremonially and recreationally for thousands of years. psilocybinproduces an altered state of consciousness (ASC) si milar to LSD, characterized by [CONTACT_220319], mood, and thought, including changes in the experience of time, space, perceptual hypersensitivity, illusions, and pseudohallucinations (i.e. hallucinations with intact reality testing and insight) 
intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones (Fischer, 1971; Geyer and Vollenweider, 2008; Isbell, 1959; Leuner, 1962; Nichols and Chemel, 2006; R√ºmmele and Gnirss, 1961; Wolbach et al., 1962). These effects are similar to those of LSD, except of shorter duration (4-6 hours instead 
of 8-12 hours) and psilocybin tended to produce less anxiety, fewer panic reactions and affective disturbances, and milder vegetative side effects than LSD.     Direct pharmacologic effects of psilocybin appear to occur through stimulation (agonism) of variousserotonin receptors, including 5-HT2A, 5-HT2B, 5-HT2C and 5-HT1A. The 5-HT2A receptor seemsparticularly important as many, but not all of psilocybin's effects are blocked by 5-HT2A receptor antagonists. Serotonergic hallucinogens such as psilocybin are considered relatively safe physiologically and do not produce dependence (Johnson et al., 2008; Leuner, 1981; Nichols, 2004).     Studerus et al., 2011, summarized patient experi ence, physiologic effects and follow-up from 8 studies in
which 110 non-psychiatrically ill volunteers were given oral psilocybin 2-28 mg (depending on the study) orplacebo and followed for up to 16 months. They report the following dose-dependent symptoms (i.e., the higher the dose, the greater the effect):
- Positive experienced derealization
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 6- Positive experienced depersonalization
- Changed sense of time- Positive mood- Mania‚àílike experience
- Anxious ego dissolution- Negative experienced derealization- Thought disorder- Paranoia- Loss of thought control- Loss of body control- Visionary restructuralization- Elementary hall. & illusions- Scenery hallucinations- Synesthesiae (that is, stimulation of one sensory organ elicits a response from another sensory organ)- Changed meaning of percepts- Facilitated recollection- Facilitated imagination
Psychological Adverse Events included:
- inactivation- poor concentration- tiredness- dazed state- introversion- self-confidence (initially increased, later slightly decreased)- heightened mood- emotional excitation- sensitivity- slight increase in anger- apprehension-anxiety- depression- dreaminess
Most of these adverse events returned to or toward baseline by 24 hours. The main exceptions were what 
they call "inactivation" and "tiredness" which remained nearly as high at 24 hours as at 3 hours. In addition, though closer to baseline, concentration remained decreased and dazed state and dreaminess were still increased at 24 hours. Griffith, et al. (2016) reports next  day headache even with low dose psilocybin (1 mg or 
3 mg).
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 7Physical Adverse Events included (in parentheses are % experiencing at highest dose [.315 mg/kg = 22 mg in a 
70 kg person (154 pounds)]):- fatigue (60%)- exhaustion (22.5%)- headache, head pressure or facial pain (37.5%)
- lack of energy (22.5%)- excessive sleep requirement (15%)
- fast exhaustibility (17.5%)- lack of appetite (17.5%)- heavy or tired legs (12.5%)- sleeplessness (5%)- abdominal pain (7.5%)- throat pain/irritation (7.5%)- diarrhea (7.5%)
Long-term Negative Effects
We found a single case report of persistent psychological effects ("flashbacks") following psilocybin use (Espi[INVESTIGATOR_220292]., 2005). Griffiths et al. (2016), followed 51 depressed and/or anxious terminal cancer patients for 
six months after they received 30 mg or 22 mg of psilocybi n, reporting ‚Äúall . . . adverse events resolved fully by 
[CONTACT_220320]‚Äù except headache which persisted into the next day in two subjects, and "There were no cases of hallucinogen [sic] persisting perception disorder or prolonged psychosis.".     While not definitive, given there are hundreds of  reported dosings of psilocybin plus unknown numbers of
recreational usages, a single case report suggests continuing  symptoms long past the drug's active effects are
likely ra re. Several authors point out that early reports of  continuing flashbacks following uncontrolled use of 
hallucinogens mainly refer to LSD, not psilocybin, and did not address whether other drugs were also used or whether pre-existing psychiatric conditions that will be excluded in the present study were also present. Also, such uses were rarely closely monitored by a facilitator as will occur in the present study.     We are not aware of a study comparing facilitator to no facilitator. Intuitively, it makes sense that having
someone present who might assist the individual in making sense of their experience might mitigate againstit being as negative an experience as it might otherw ise be, and we are not aware of reports of "flash-backs"
or other late negative effects in individuals who used  psilocybin in the presence of a trained facilitator.
Addiction Potential
As psilocybin is a Schedule I drug (meant to mean "no currently accepted medical use and a high potentialfor abuse") it is reasonable to have concern that study  participants will become addicted to psilocybin. Our
understanding is there is no documented case of an individual becoming addicted to "magic mushrooms" orpsilocybin. In fact, individuals who have used either magic mushrooms or psilocybin repeatedly spacetheir use out as if their repeat use is less than several months after a prior use, they achieve only a fraction of
the earlier effect. This also argues against there being addiction potential for this compound.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 8Rationale for the Psilocybin Doses use in this Study
Carhart-Harris, et al. (2016), suggested efficacy for depression with 10 and 25 mg and Griffiths, et al. (2016) found [ADDRESS_264673] adverse events being transient (1-3 hours) and mild, while Griffiths decreased their "high dose" from 30 mg to 22 mg because of poor tolerance of the 30 mg dose (vomiting); they reported [ADDRESS_264674]. Both 
Carhart-Harris and Griffiths reported the only delayed (n ext day) adverse events were headaches lasting < 24 
hours. Personal communication with Carhart-Harris (2019), supported use of the 25 mg dose as optimal to maximize efficacy while minimizing risk of adverse events, based on his published studies and subsequent unpublished experience with psilocybin.
6SHFLILF$LPVDQG+\SRWKHVHV
Concisely state the objectives of the study and the hypothesis or primary research question(s) being examined.  There 
should be one hypothesis for every major study procedure or intervention.  For pi[INVESTIGATOR_7602], it is important not to overstate the study's objectives.  If there are no study hypotheses, describe broad study goals/aims.
1. Psilocybin will be acceptable to, and safe and well tolerated by, patients with BDD2. Symptoms of BDD will improve after psilocybin administration, with persistent improvement over [ADDRESS_264675]-
treatment
'HVFULSWLRQRI6XEMHFW3RSXODWLRQ
In this section, you are to describe each subject population of the study.  The demographics of the population should reflect the gender and ethnic distribution of each population being studied.  Enter each subject population‚Äôs sample size, Gender, Racial, and Ethnic breakdown, and finally, describe each subject population.
Example:
Sample subject population:
Subject Population Number of completers 
required to accomplish Projected number of 
subjects who will be enrolled to obtain required Age range of subject 
population
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 9study aims number of completers
Adults with BDD 12 12 18-55
Gender, Racial, and Ethnic Breakdown:
Gender Breakdown4 male participants8 female participantsRacial Breakdown8 White participants3 Asian participants1 particopant who identified as ‚ÄúOther‚ÄùEthnic Breakdown11 Non-Hispanic/Latinx Participants1 Hispanic/Latinx participantDescription of subject population:Study sample will consist of adult participants between the ages of 18-55 with a diagnosis of Body Dysmorphic Disorder.
6XLFLGH5LVN0DQDJHPHQW3ODQ
This section will include all information regarding the Suicide Risk Management Plan.  
  The study is in data analysis and is not currently enrolling or  recruiting participant so this would not be applicable to us.
5HFUXLWPHQW3URFHGXUHV
This section will include all information regarding your study‚Äôs recruitment process/procedures.  
Describe settings where recruitment will occur.  Virtual through websites RecruitMe.com, Craigslist and 
ClinicalTrials.gov. Recruitment has ended for this study.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 10How and by [CONTACT_40402]/or recruit ed?  Recruitment has closed for this study as of April 2022. 
When recruitment was open, sujects were recruited through the above websites and were approached by [CONTACT_2420], Gloria Gomez.
How will the study be advertised/publicized?  Study will be advertised on the above websites, but recruitment has 
closed as of April 2022.
Attach any ads/recruitment materials requiring review at this time in the Uploads section.Clinical Trials:
Please provide the NCT Registration Number for your Clinical Trial.  [STUDY_ID_REMOVED]
YOU MUST REGISTER AT ClinicalTrials.gov  IMMEDIATELY UPON RECEIPT OF IRB APPROVAL AND PRIOR TO 
ENROLLMENT  OF THE FIRST SUBJECT.  YOU WILL BE PROVIDED WITH A NCT REGISTRATION NUMBER ON 
REGISTRATION.  PLEASE REVISE THIS SECTION OF TH E PROTOCOL SUMMARY FORM TO INCLUDE THE NCT NUMBER 
AND RE-SUBMIT AS AN AMENDMENT TO THE IRB.
&RQFXUUHQW5HVHDUFK6WXGLHV
In this section, please identify if subjects in this study  participate in or will be recruited from other studies.  
Describe where subjects are recruited from.   N/ADescribe the recruitment source for (Must provide IRB Number, PI [CONTACT_13693]).  N/A
,QFOXVLRQ([FOXVLRQ&ULWHULD
This section details your study sample(s) and addresses the requirement for risk minimization.
You may choose to divide your sample by [CONTACT_66067] (healthy controls vs. patient population) or by [CONTACT_42540] (subjects who will have an MRI vs. those who will not) and then define different sets of criteria for each.
For each sample, create or insert a table to describe detailed criteria for study inclusion and exclusion and the method 
you will use to ascertain each criterion. The method of ascerta inment may describe tests, scales and instruments.  When 
relevant, indicate the level of training of the person who will make the assessment (e.g. clinical interview by a psychiatrist).
Inclusion/Exclusion Criteria need to be numbered and listed in outline form (see Table template below).
Adults (18-55) with a Diagnosis of Body Dysmorphic Disorder
CRITERION                                                         METHOD OF ASCERTAINMENT               
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 11Inclusion:
1.Age 18-55 Date of birth
2. DSM-5- body dysmorphic disorder, 
non-delusional subtype, for >6 months by [CONTACT_969]. Non-delusional subtype will be operationalized by [CONTACT_220321] (BABS) 6-item total <18 (Phillips et al., 2006)SCID -[ADDRESS_264676] moderate severity of BDD, 
operationalized by [INVESTIGATOR_182913] >24 on the Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS), BDD-YBOCS
4. At least moderate overall severity, 
operationalized by [CONTACT_220322] (4 or greater) on the CGI severity scaleCGI severity scale
5. History of intolerance of, or 
nonresponse to, a prior adequate trial of an SSRI (> 2 months of fluoxetine 20 
mg/day or equivalent), SNRI, or 
clomipraminePsychiatric History
6. Currently in psychotherapy (other than 
CBT for BDD)Psychiatric History
7. Able to provide informed consent Psychiatric Assessment
Exclusion:
1. Current major depressive disorder of 
greater than moderate severity (17-item Hamilton Rating Scale for Depression total >20) Hamilton Rating Scale for Depression
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264677] 3 months, or positive result on urine drug screen for illicit substance of abuse (except that prior cannabis use subthreshold for abuse diagnosis will be permitted if discontinued >24 hours prior to dosing)MINI, urine drug screen
4. Current clinically significant suicidality 
or a suicide attempt within the past yearPsychiatric Assessment, MINI, CSSR (items 3 
or 4 rated ‚Äúyes‚Äù for active suicidal ideation) 
5. Need for inpatient or partial hospi[INVESTIGATOR_220293]
6. Mental retardation, dementia, brain 
damage, or other cognitive impairment that would interfere with participation Psychiatric Assessment and History
7. Body image concerns accounted for 
primarily by [CONTACT_220323]
8. Body dysmorphic disorder criteria not 
met if weight concerns are excludedPsychiatric Assessment
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 139. Use of: investigational medication 
within past  3 months; depot 
antipsychotic within past  6 months; 
serotonergic medication within past  2 
weeks (6 weeks for fluoxetine). The ADC will not take subjects off medication for the purpose of entering this study.Psychiatric and Medical History
10. Current cognitive-behavioral therapy 
(CBT) specific for BDD Psychiatric History
11. History of seizure disorder, other than 
febrile seizure in childhood  Medical History
12. Presence of significant or unstable 
medical illnessMedical History, vital signs, EKG, blood and 
urine tests, physical examination
13. Females who are pregnant, 
breastfeeding, or sexually active and not willing to use adequate contraception Medical History, urine pregnancy test
14. Presence of any other conditions that 
would preclude safe administration of psilocybin based on clinical judgement of the PI [INVESTIGATOR_1238]/or therapi[INVESTIGATOR_541]. This includes but is not limited to any behaviors suggesting the participant will be unable to establish therapeutic alliance with the therapi[INVESTIGATOR_220294]
15. Enrollment in any investigational drug 
or device study in past 30 daysPsychiatric History
16. Dissociative Disorder Psychiatric Assessment
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 1417. Prior adverse effects from psilocybin Psychiatric History
&RQVHQW3URFHGXUHV
Explain, in this section, the procedures for obtaining consent from study participants.
If the eligibility screening for this study is conducted under a different IRB protocol, enter the NYSPI [CONTACT_1744]# 7094R
Currrently, the  study has concluded and is not enrolling or recruiting new participants. When the study was enrolling 
participants, consent was obtained by [CONTACT_220324], Franklin Schneier, MD, Rapahel Campeas, MD, and Jose 
Arturo Sanchez Lacay, MD.  7950 participant consent forms were stored on our REDCap database. Consent procedures were also documented in EMR Progress Notes by [CONTACT_15098]. 
:DLYHURI&RQVHQW$XWKRUL]DWLRQ
The following sections are to be completed for the appropriate waiver/alteration of consent.  
:DLYHURI&RQVHQWIRUXVHRI3URWHFWHG+HDOWK,QIRUPDWLRQ3+,
What records do you wish to review? N/A
What information are you seeking access to?  N/ADescribe your plan to protect identifiers from improper use and disclosure.  N/ADescribe your plan to destroy the identifiers as soon as possible, consistent with the conduct of the research, or 
provide a health or research justification for retaining the identifiers or explain how retention is required by [CONTACT_2371].  N/A
Explain why the research could not be practicably carried out without the information (for which you are 
requesting access).  N/A
Explain why the research cannot be practicably carried out without the waiver.  N/AExplain how/if subjects will be provided with additional pertinent information after participation.  N/A
-XVWLILFDWLRQIRU:DLYHURU$OWHUDWLRQRI&RQVHQW
Waiver of consent is requested for the following.  N/AExplain why your research cannot be practicably carri ed out without the waiver or alteration.  N/A
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 15Describe whether and how subjects will be provided with  additional pertinent information after participation.  
N/A
:DLYHURI'RFXPHQWDWLRQRI&RQVHQW
Would the consent form signature [CONTACT_60510]‚Äôs identity and the research data? N/A
Is breach of confidentiality the main study risk? N/AIs consent for this research procedure ordinarily not required outside of the research context?  Explain.  
N/A
Describe the study component(s) for which waiver of documentation is requested.  N/A
:DLYHURI3DUHQWDO&RQVHQW
Explain why parental/guardian consent is not a reasonable requirement to protect the minor participants in this 
study.  N/A
If parental consent is waived, describe a mechanism that  will be substituted to provide appropriate protections 
for the subjects.  N/A
$VVHQW3URFHGXUHV
In this section, please describe the procedures by [CONTACT_220325] / or recorded.
N/A
3HUVRQV'HVLJQDWHGWR'LVFXVVDQG'RFXPHQW&RQVHQW
Please list all the names of persons designated to obtain c onsent / assent.  All persons must complete CITI training for 
NYSPI.  The PI [INVESTIGATOR_220295].
Franklin Schneier, MDRaphael Campeas, MDJose Arturo Sanchez Lacay, MD
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 16,QGHSHQGHQW$VVHVVPHQWRI&DSDFLW\
This section is designated for those studies  that have been identified where subjects May Lack  capacity to consent.  
Describe the Methods/procedures for capacity assessment.  N/AIf your study involves subjects who DO LACK  capacity to consent, please justify.  N/A
Procedures for surrogate consent.  N/A
6WXG\3URFHGXUHV
Provide a clear, concise narrative of study procedures with special attention to the subjects' involvement.  Detail the 
overall study timeline and location of study procedures, list all interventions, assessments and interviews, estimate the duration of each procedure, provide dosing schedules, identify study personnel involved in each procedure, and provide 
credentials for relevant personnel.  If treatment is prov ided, specify the minimum credentials for providing that 
treatment. For complicated study designs, we strongly encourage attaching tables, flow-charts, and study algorithms.
I attest to follow the COVID-19 Safety Guideline for Columbia Psychiatry and NYSPI [INVESTIGATOR_40372]-Entry outlined in the 
NYSPI [INVESTIGATOR_40373]‚Äôs June 1, 2020 memo, which include but are not limited to:
‚Ä¢Infection Control/PPE ‚Äì Guidelines
‚Ä¢Research participants will only come on-site if absolutely necessary for study procedures.
‚Ä¢Clinical research teams will screen heir participants for COVID symptoms (night before and day of 
onsite visit, documenting this in the chart), and escort them in and out of the building.
‚Ä¢COVID/COVID-like symptoms in participants will be reported to the IRB via PRISM as an SAE.
COVID testing: Depending on COVID conditions in th e community, the participant and the two therapi[INVESTIGATOR_220296], to determine if any may currently be infected with the virus that causes COVID-19. The test involves collecting a sample by [CONTACT_220326] a cotton swab several inches into the nose. If the 
test shows that the participant or either therapi[INVESTIGATOR_220297]-19, your research treatment visit will be postponed.
Internet-based data collection or transmission will be conducted following HIPAA and NYSPI [CONTACT_21401].1. Visit 1 (Screening). A complete psychiatric and physical examination will be performed, including
Psychiatric, Medical and Social Histories, MINI Structured Psychiatric Interview, SCID-[ADDRESS_264678] laboratory testing including 
EKG, urine for routine analysis, drugs of abuse and (if appropriate) pregnancy and blood for hematologies and 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 17chemistries including thyroid function. A physical examin ation will be performed at the screening or between 
screening and Visit 2 (Day -1), with results obtained before psilocybin administration day. 
Additional screening will specifically assess eligibility for the MRI portion of the study with the self-rated 
PhenX Toolkit Hand Dominance Measure and MRI Metal Screening Questionnaire. Contraindications to MRI scanning are:
‚Ä¢Paramagnetic metallic implants or devices
‚Ä¢Contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the 
body (e.g., pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos)
‚Ä¢Being unable to tolerate the scanning procedures (i.e., severe obesity, claustrophobia)
Patients with contraindicated metal or left-handedness will not be offered MRI participation but will complete 
all other parts of the protocol.
 
Additional visits (V1a, V1b) will be scheduled as needed to follow up on any lab abnormalities and for patient to establish relationship with study therapi[INVESTIGATOR_541]. 
Participants will be invited to bring to the screening a companion (friend/family member) whom they would 
like to support them through the study. Such a companion will be informed of their potential role and will be asked to sign a ‚Äúcaregiver‚Äù consent form at the Screening Visit. Caregivers will receive information about the signs of worsening of depression and suicide risk a nd ways to contact [CONTACT_220327]. The 
caregiver will complete a questionnaire at screening, Week 3 and Week 12. 
2. Visit 2 (Baseline, Day -1) . Eligibility and willingness to participate will be reassessed. At this visit, the patient 
meets with the therapi[INVESTIGATOR_220298]. MRI-eligible subjects will complete acquisition of resting state fMRI. Subjects will also complete an invert ed face computer task in which they will view an image 
of a face and then will be shown an image of two faces (one matching and one non-matching morphed face) and asked to select the matching face as rapi[INVESTIGATOR_220299]. The matching and non-matching faces will be presented either upright or inverted, in various combinations. This task assesses global vs. local visual processing, and it has previously been shown to be abnormal in BDD (Feusner, 2010).
3. Visit 3 (Psilocybin Day, Day 0). The next day, a study psychiatrist again assesses eligibility; those eligible and 
agreeable receive their dose of psilocybin (25 mg) and spend the next eight hours (longer if needed) with the two therapi[INVESTIGATOR_11437]; when deemed appropriate, the patient is accompanied home either by a person of their choosing or a staff member. The patient will be reminde d that they should not drive or drink alcohol at least 
until after the end of Visit 4 (next day). Vital signs are taken prior to their dose of psilocybin and prior to leaving the clinic and a study psychiatrist evaluates prior to their departure for whether their condition requires them not to leave. In the latter case, they w ill either remain in the Biological Studies Unit (BSU) until 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264679] or admitted to 5-Sout h inpatient service if they require additional observation 
overnight.
Psychological Approaches to Anxiety
‚Ä¢During Visit 2 and prior to ingestion of psilocybin dur ing Visit 3, explain anxiety, even fear, may occur
‚Ä¢During Visit 2, train patient in relaxation and breathing techniques that may alleviate anxiety
‚Ä¢On Visit 3, shortly after psilocybin ingestion, rem ind subject of possible anxiety reaction and that 
therapi[INVESTIGATOR_220300]
‚Ä¢During Visit 3, if patient reports excessive anxiety or fear, walk them through relaxation and breathing 
techniques taught during Visit 2
‚Ä¢Encourage exploration of psilocybin experience
‚Ä¢Call M.D. if fear is not alleviated by [CONTACT_220328]
‚Ä¢Anxiety: Lorazepam or alprazolam
‚Ä¢Psychosis: Risperidone
‚Ä¢Headache: Acetaminophen
‚Ä¢Symptomatic elevation in BP: Beta-blocker (e.g., propranolol)
‚Ä¢Nausea/vomiting: Ice chips
Hospi[INVESTIGATOR_220301]
‚Ä¢Given prior experience with psilocybin treatment, the need for inpatient hospi[INVESTIGATOR_220302]
‚Ä¢In the event that patients require hospi[INVESTIGATOR_220303] 5-South unit.
‚Ä¢Prior to psilocybin dosing [CONTACT_220346] will be contact[INVESTIGATOR_530] (email or text [PHONE_4672]) to ascertain
‚Ä¢whether backup 5S inpatient bed at NYSPI [INVESTIGATOR_5915]. In event of lack of availability for such a 
bed on 5S after it has been offered (e.g., unanticipated issue on inpatient unit) the NYPH. Emergency Room will serve as backup.
4. Visit 4 (Post-Psilocybin Day 1). The patient returns to the anxiety clinic and reports any experiences since
leaving the clinic as well as having blood, urine, and EK G tests. MRI eligible patients will have another resting 
state fMRI session, The inverted face task will be repeated.
5. Visits 5-8 (Post-Psilocybin Weeks 1-3 and 12). The patient returns 1, 2, [ADDRESS_264680] evaluation of psychiatric symptoms, functioning and AE's. These visits may be conducted by [CONTACT_40425].
6. Telephone visits (Weeks 6 & 9). The patient is contact[CONTACT_5143] 6- and 9-weeks post-psilocybin
for standard evaluation of psychiatric symptoms and AE's.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 197. Early Withdrawal Visit. Should the patient or study doctor decide to end the study visits prior to Week
12, if the patient agrees, all Visit 10 (Week 12) ratings including Independent Evaluation will be made.
Extra Visits
1. Extra visits (or in-person visits when phone visits are called for) will "kick in" if:2. Patient reports on-going or intermittent nega tive effects, including but not limited to:
a. "Flash-backs"b. Psychotic or quasi-psychotic (e.g., illusions, non-paranoid worries re. how others are viewing or 
treating them) experiences
3. Significant (e.g., > 25% increase in BDD-YBOCS) worsening from original severity.4. Significant suicidality (e.g., patient reports suicidal thinking with any intent to act)5. Physician's clinical judgment
Detailed Procedure for Staff Escort Home
In the event that it is deemed appropriate for a patient to return home following their psilocybin experience and said patient has not provided a responsible party to accompany him or her home, a staff member will accompany the individual from the BSU treatment room to the exterior door of their home. Transportation 
will be via a car service for which we will pay. The staff member will be instructed to contact [CONTACT_220329] [INVESTIGATOR_220304], erring  on the side of further observation. Else, the staff 
member will allow the individual to enter their home and close the door, the staff member remaining outside and relieved of escort duties.
7DEOH6FKHGXOH RI6WXG\ 3URFHGXUHV
9LVLW  DEF 
HWF  
'D\ 6FUHHQ
9LVLW6FUHHQLQJ
3HULRG3VLOR
F\ELQ      
,QIRUPHG &RQVHQW ;
0HGLFDO+LVWRU\ ;;
0,1,,QWHUYLHZ ;
'RFXPHQWDWLRQRI%LUWK&RQWURO0HWKRG ;
3ULRU&RQFRPLWDQW 0HGV ;; ; ; ;;;;;; ;
+DPLOWRQ5DWLQJ6FDOHIRU'HSUHVVLRQ ;; [[ [
&ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH ;[[
%''<DOH%URZQ2&'6FDOH ;;; ;;;;;; ;
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 20%''5(%864 ; ; ; ;;;;;; ;
%URZQ$VVHVVPHQWRI%HOLHIV6FDOH ; ; ; ;;;;;; ;
3K\VLFDO([DPLQDWLRQ ;
(&* ;;
8ULQDO\VLV ; [ ;
8ULQHIRUGUXJDOFRKRO VFUHHQLQJ ;;
8ULQHIRU SUHJQDQF\WHVWLQJ
 ;;[
%ORRGIRU URXWLQHODERUDWRU\DVVD\V ;;;
9LWDOVLJQV ;;;;
+HLJKWDQG:HLJKW ;
3KHQ;7RRONLW+DQG'RPLQDQFH0HDVXUH [
05,0HWDO6FUHHQLQJ4XHVWLRQQDLUH [[ x
,QFOXVLRQ	([FOXVLRQ&ULWHULD ;;
$GYHUVH(YHQWV6$(; ; ;;;;;; ;
5HVWLQJ6WDWHI05, [[
,QYHUWHG)DFH7DVN [[
&OLQLFDO*OREDO,PSUHVVLRQ&KDQJH;;;;;; ;
'LPHQVLRQ$OWHUHG6WDWHVRI&RQVFLRXVQHVV ;
(PRWLRQDO%UHDNWKURXJK,QYHQWRU\ ;
3RVLWLYHDQG1HJDWLYH$IIHFW6FKHGXOH ;; [[
/LHERZLW]6RFLDO$Q[LHW\6FDOH [ ; [ ;
3V\FKRORJLFDO,QVLJKW6FDOH ; xx [
6RPDWRPDS ‚Äì'7RRO [ [[
6KHHKDQ'LVDELOLW\6FDOH ; x ;
4XDOLWDWLYH,QWHUYLHZ [[
6OHHS4XHVWLRQQDLUH [ [
'\VPRUSKLF&RQFHUQV4XHVWLRQQDLUH [ [ xx [
At any visits in which patient reports clinical worsening, HamD, CSSR, and CGI will be repeated.
&ULWHULDIRU(DUO\'LVFRQWLQXDWLRQ
Define criteria that will be used to exit or drop subjects fr om the study and operationalize.  Indicate the time points when 
such criteria will be applied, and describe the rating instrume nts, parameters, and thresholds that will lead to a decision 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264681]'s participation  and the role of the person who will make these determinations. Studies which 
include a medication taper and discontinuation may be asked to include an independent medical monitor (an MD not on the study team) who will aid the study team in determining whether study discontinuation is needed.   In addition, explain procedures for managing subjects who are withdrawn from the protocol.
For treatment studies: To minimize risks to subjects, operationalized drop-out criteria should be defined so that subjects 
who worsen, or in some cases, fail to improve, are removed from the study and offered standard care.  The threshold for drop-out should consider the level of risk associated with non-improvement for the specific disorder, the availability of alternatives, and the typi[INVESTIGATOR_220305].  For example, emergence of suicidal intent, or psychosis, should prompt immediate clinical evaluation and withdrawal from the study.
1. Patient withdraws consent
2. Study personnel determines it is not in the pa tient's best interest to continue in the study. 
3. Clinical worsening
4. At each assessment participants will be evaluated for clinical worsening, and any participant who 
reports symptomatic worsening (CGI Change Score >4) will be further evaluated for need for urgent clinical treatment. Further evaluation will include the Hamilton Depression Scale, the Columbia Suicide Severity Rating Scale (C-SSRS), and the Clinical Global Impression Change Scale, but the ultimate decision to provide or refer to non-st udy treatment will be based on clinical judgement, 
with reasoning documented in the chart. 
5. Any participant who evidences need for non-study  clinical treatment before psilocybin 
administration  will be removed from the study and offered appropriate referrals, including 
transitional treatment in the Anxiety Disorders Clinic, or being walked to the emergency room if indicated. After psilocybin administration, clinical deterioration will be treated the same way, except that patients will be permitted to conti nue participation in remaining study assessments.
6. Potential pregnancy: Participants who prior to dosing have a positive pregnancy test or report 
suspecting pregnancy will be removed from the study.  Participants who after dosing have a positive pregnancy test will be excluded from th e repeat MRI but will be allowed to continue in 
study assessments of symptoms.  They will be offered assistance with obstetrical follow-up
%ORRGDQGRWKHU%LRORJLFDO6DPSOHV
Describe how the sample will be used and indicate, when relev ant, the amount of the sample.  The IRB wants to know 
that the sample is sufficient for the purposes of the study, but t hat sampling is limited to what is minimally necessary.  
If you‚Äôve indicated that you intend to store a sample for futur e use, indicate where the sample will be stored, how long 
the sample will be stored, and to what purposes the sample will eventually be put.  Check the IRB website at 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 22https://irb.nyspi.org/investigators/guidance/genetic-research    for specific guidance and additional information about 
future use of DNA samples.
Blood will be drawn for routine testing of hematology (i .e., number, size and hemoglobin content of red blood 
cells and number and type of white blood cells) and chemistries (e.g., liver enzymes, electrolytes andrenal function) on each of three occasions: initial evaluation, 1day post psilocybin and three weeks postpsilocybin. Approximately 20 cc (= 4 teaspoons) of bl ood will be obtained on each occasion, or 60 cc = [ADDRESS_264682], 500 cc is taken on a single occasion when one donates blood.
$VVHVVPHQW,QVWUXPHQWV
List all assessment instruments, indicate who will administer them and their credentials/qualifications. Provide an 
estimate the duration of each measure.  The IRB wants to kn ow that assessments instruments are appropriate measures 
for the purposes of the study and are no more burdensome than necessary.  The IRB will consider the burden of assessment instruments (in terms of time, sensitivity of material, et c.) in the risk/benefit analysis.  Please attach copi[INVESTIGATOR_220306]-standard instruments.
‚Ä¢5D-ASC ‚Äì The Five Dimension Altered States of C onsciousness Questionnaire measures the acute drug 
effects in terms of various ways of determining state of consciousness. 10 min.
‚Ä¢BDD-YBOCS ‚Äì The Yale-Brown Obsessive-Compulsive Scale Modified for BDD is a standard clinician-
rated measure of BDD symptom severity. 10 min.
‚Ä¢BDD-REBUS-Q ‚Äì 2-item questionnaire rating certainty of negative beliefs about self and appearance. 1 
min.
‚Ä¢BABS ‚Äì The Brown Assessment of Beliefs Scale is a clinician-rated scale assessing the intensity of body 
image belief in BDD. 10 min.
‚Ä¢CGI Clinical Global Impression Scales, Severity and Change ‚Äì global clinician-rated measures of 
symptom severity and Change 5 min.
‚Ä¢CSSR ‚Äì Columbia Suicide Severity Scale 10 min.
‚Ä¢EBI ‚Äì The Emotional Breakthrough Inventory is an 8-item brief measure intended to index the degree 
to which an individual experiences his/her emotion dur ing a psilocybin session. It is a visual analogue 
style scale,  typi[INVESTIGATOR_220307] 0 to 100. 5 min
‚Ä¢QLESQ ‚Äì The Quality-of-Life Enjoyment and Satisfaction Questionnaire is a self-rated measure. 5 min.
‚Ä¢HAM-D-17 ‚Äì The 17-item Hamilton Rating Scale for Depression measures the degree of symptom 
severity in depressed patients.
‚Ä¢Liebowitz Social Anxiety Scale ‚Äì 24 item scale assessing fear and avoidance of social anxiety 5 min
‚Ä¢MRI Metal Screening Questionnaire - self-rated 5 min.
‚Ä¢MINI - the Mini International Neuropsychiatric Interview, Version 7.0.2, is a standardized, semi-
structured interview that produces DSM-5 diagnoses. It is similar to the SCID. 30 min
‚Ä¢PANAS - Positive and Negative Affect Schedule measures the acute emotional drug effects.5 min
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 23‚Ä¢PhenX Toolkit Hand Dominance Measure ‚Äì self rated form 5 min.
‚Ä¢Psychological Insight Scale ‚Äì 7 question assess changes in insight on a visual analogue scale. 5 min
‚Ä¢Qualitative Interview 
‚Ä¢SDS ‚Äì The Sheehan Disability Scale is a patient-reported outcome measure used to assess functional  
‚Ä¢impairment and associated disability. 5 min.
‚Ä¢Somatomap 2D (Ralph-Nearman et al. 2019) ‚Äì A HIPAA-compliant web-based self-assessment tool for 
measuring body image perception. It displays an androg ynous manikin; the user is asked to imagine it 
as their own body and draw directly upon it to outline an area of bodily concern. They then provide emotion ratings for each area of concern. Somatomap was built on Chorus, a HIPAA (Health Insurance Portability and Accountability Act)-compliant visual development platform. Chorus is a hosted service provided through the University of [LOCATION_004] Los Angeles (Areivan et al., 2018). 15 min
‚Ä¢Sleep Questionnaire ‚Äì 2 items assessing sleep quantity and quality.
‚Ä¢Dysmorphic Concerns Questionnaire (Oosthuizen et al ., 1998) ‚Äì A 7-item self-rated scale assessing 
dysmorphic beliefs.
6HFWLRQVWREHFRPSOHWHGIRU VWXGLHVXVLQJ,1','('UXJVDQG'H YLFHV
Prior to the submission of any study involving a faculty held IN D or IDE being approved by [CONTACT_1201], the IND/IDE holder is 
required to submit a form  signed by [CONTACT_38240]/IDE holder and PI.
Which are applicable to your study:   Drug    Device    Radiolabeled drug/compound
2II/DEHODQG,QYHVWLJDWLRQDO8VHRI'UXJV
Enter the information for all drugs to be used in this study:
Name [CONTACT_220342] (select one) IND application is pending
IND is approvedNo IND is required
IND #Who holds the IND (i.e., IND Sponsor). 
If other than PI/CU Investigator, type name [CONTACT_220343].
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 24Which applies: FDA has determined the IND is not required (provide 
correspondence)
FDA conditions are met (see ‚ÄúRules‚Äù) ‚Äì Explain
2II/DEHODQG,QYHVWLJDWLRQDO8VHRI'HYLFHV
Enter the information for all devices to be used in this study:
Name [CONTACT_220344] (select one) IDE application is pending
IDE is approvedNo IDE is required
IDE #Who holds the IDE (i.e., IDE Sponsor). If 
other than PI/CU Investigator, type name [CONTACT_220343].
Is the device marketed?Which applies: FDA has determined that IDE is not required
FDA conditions are met (see ‚ÄúRules‚Äù) ‚Äì ExplainDevice is ‚ÄúNon-significant risk‚Äù ‚Äì Explain
2II/DEHODQG,QYHVWLJDWLRQDO8VHRI5DGLRODEHOHG'UXJV&RPSR XQGV
Enter the information for all radiolabeled drug/compounds to be used in this study:
Name [CONTACT_220345]/compoundN/A
Manufacturer and other Information N/A
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 25Approval Status (select one) IND application is pending
IND is approvedRDRC approval is pendingRDRC is approvedNo FDA/RDRC approval is required - Explain
IND # N/AWho holds the IND (i.e., IND Sponsor ). 
If other than PI/CU Investigator, type name [CONTACT_220343].N/A
5HVHDUFK5HODWHG'HOD\WR7UHDWPHQW
Research involving participants who are in need of treatment invariably involves delay to care, and this delay is 
associated with risk.  Scheduling of procedures must be carefully organized to minimize delay.  Other delay must involve only that minimally necessary to accomplish the aims of the research while respecting subject well- being and safety. 
Describe the delay, by [CONTACT_220330], before a participant can receive treatment of known 
efficacy or standard care routinely offered in the community.
Participants in the study will need to be free of SSRI medication for at least 2 weeks prior to psilocybin administration and for 3 weeks thereafter, so total delay to an established treatment will be 5 weeks. Patients who for clinical reasons need treatment intervention sooner will be offered established treatment. If patients need to restart SSRI‚Äôs prior to the psilocybin session, they will be excluded. If they restart after the session, the reason will be documented, and the patient will be followed until the end of study visit provided that informed consent is maintained.
&OLQLFDO7UHDWPHQW$OWHUQDWLYHV
Describe what other treatment or assessment options are av ailable to subjects who do not participate in research.
There are no FDA-approved medications for BDD, but SSRIs and specialized BDD-specific CBT have been shown 
to be efficacious in controlled trials. 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 265LVNV'LVFRPI[INVESTIGATOR_81622],QFRQYHQLHQFHV
"Risk" is a broad term used to convey the potential for  harm, burden, and inconvenience related to research 
participation.  Use this section to provide a comprehensive description of foreseeable physical, psychological, social, interpersonal, and economic risks introduced by [CONTACT_53775].  Include the source of the information.  Consider both the probability and magnitude of harm and its impact.  Describe the foreseeable harms associated with the research (untoward effects of a medication) and those related to delay to individualized treatment.  Include data from the literature, and local data, if available, on risk rates and subject experiences with research procedures. Describe procedures in place to minimize risk. In general, please create a numbered list of risks/categories of risk, and in general put the list in the order of significance or level of risk, the most significant risks should be listed first. 
1. BDD might not remit or may worsen
2. Psilocybin has not been extensively studied, so both short and especially long-term consequences of its 
use may not be known at present
3. Known psychological effects of psilocybin include:
a. Euphoric moodb. Dissociative experience (i.e., feeling outside one's body or unreal, a distorted sense of timec.Hallucinations (which may persist for weeks after dosing)
d. Psychotic experience such as paranoiae. Difficulty with cognition (e.g., trouble adding or solving puzzles)f. Disturbance in attentiong. Mood alterationh. Inappropriate affect (e.g., crying when one is not sad or laughing when nothing odd occurred)
4. Known medical effects of psilocybin include:
a. clumsinessb. feeling weakc. headached. hyperreflexia (e.g., the lower leg reacts too strongly when the knee tendon is tapped)e. hyporeflexia (e.g., the lower leg under-reacts when the knee tendon is tapped)f. increased blood pressureg. increased pupil sizeh. rapid heart beati. tremorj. vomiting
5. Discomfort of needle sticks and ECG6. Time commitment to completing forms, and attending evaluation, treatment and follow-up sessions7. Harm to an unborn or newborn child8. MRI
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 27Describe procedures for minimizing risks:
1. BDD might not remit - standard medication treatment, such as with an SSRI will be instituted and 
patient will be referred for CBT or other therapy as clinically indicated.
2. Psilocybin has not been systematically studied, so both short and especially long-term consequences of 
its use may not be known at present - while unknown risks cannot be minimized, we will minimize the 
likelihood of such risks occurring unnoticed during the study period by [CONTACT_220331]'s at every post-psilocybin visit and encouraging patients to call between visits should any untoward events occur, whether they think they may be related or not.
3. Known psychologic effects of psilocybin include:
a. Euphoric mood - the risk of feeling too good is it can result in rash behavior, as in mania. We 
anticipate that if euphoria occurs, it will happen on the psilocybin day when the therapi[INVESTIGATOR_220308]. As overly euphoric mood is a characteristic of bipolar  illness, so to minimize risk the study excludes 
patients with known bipolar disorder. 
b. Dissociative experience (i.e., feeling outside one's body or unreal, a distorted sense of time) ‚Äì 
We anticipate that if the patient has a dissociative experience, it will occur on the psilocybin day when the therapi[INVESTIGATOR_220309] "talk them down" and other clinicians will also be readily available.
c. Hallucinations - as with b)d. Psychotic experience such as paranoia - as with b); our anticipation is psychotic experiences will 
spontaneously remit within hours of the subject receiving psilocybin. If not, the on-call psychiatrist can determine whether to give an antipsychotic medication.
e. Difficulty with cognition (e.g., trouble adding or solving puzzles) - again, this will occur on the 
psilocybin day and will be minimized by [CONTACT_2111][INVESTIGATOR_34722], and it is anticipated to dissipate by 
[CONTACT_220332], or at least by [CONTACT_58079]. 
f. Disturbance in attention - this is also anticipated to mainly occur on the day the patient receives 
psilocybin, but its impact on functioning will be monitored out to Week 12 using the SDS.
g. Mood alteration ‚Äì mood will be monitored using the HAM-D-[ADDRESS_264683] (e.g., crying when one is not sad or laughing when nothing odd occurred) ‚Äì 
this will be monitored by [CONTACT_220333][INVESTIGATOR_541]'s interaction with the patient.
4. Known medical effects of psilocybin:
a. Clumsiness - a staff member will remain with patient at all times ready to prevent falls as 
needed (e.g., traveling to and from the bathroom)
b. Feeling weak - dittoc. Headache - standard headache remedies (i.e., NSAID's)
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 28d. Hyperreflexia - reassurance and waiting
e. Hyporeflexia ‚Äì reassurance and waitingf. Elevated blood pressure - watchful waiting as to date, the blood pressure has not been 
documented to get to dangerous levels (i.e., systolic pressure may get to 160 mm Hg); as blood pressure rises typi[INVESTIGATOR_31228] 1-3 hours, a short-acting blood pressure lowering medication such as nifedipi[INVESTIGATOR_220310]
g. Increased pupil size - keep in darkened room (this is the standard lighting in psilocybin roomsh. Rapid heartbeat - watchful waiting as to date, fast heart rate has lasted 1-3 hours; propranolol 
could be used but to my knowledge no "rescue" med has been required to date.
i. Tremor - this typi[INVESTIGATOR_34607] 1-3 hours so should not require anything besides reassurance; if 
severe enough, do not allow hot liquids
j. Vomiting - this is unusual and time limited; probably too short-lived for anti-emetic medication 
to help; could try ginger ale or ginger tea
5. Discomfort of repeated needle sticks and other procedures: experienced, trained phlebotomists will 
obtain blood
6. Time commitment to completing forms, and attending evaluation, treatment, and follow-up sessions - 
we will do everything we can to limit time spent; e.g. , if patients must wait for their doctor, they will be 
instructed to complete their self-report forms
7. Psilocybin is not considered safe during pregnancy or breast-feeding, because such safety testing has 
not been done. Therefore, potential participants will be excluded if pregnant, breast feeding or planning to become pregnant during the next [ADDRESS_264684] twice during the study (on the day prior to taking psilocybin, 
and on the day taking psilocybin). Participants will be cautioned that even if a pregnancy test is negative, they could still be pregnant, because these tests cannot detect very early pregnancies (that is, within the first few days). Participants will be excluded if they do not agree use an effective form of birth control before and throughout study participat ion. Methods of birth control considered to be 
effective include double barrier methods (condom plus spermicide, or diaphragm plus spermicide), birth control pi[INVESTIGATOR_3353], birth control shots and intrauterine devices. Men who are sexually active will also be excluded if they do not agree to using adequate contraception. Female partners of men participating in this study should use one of the acceptable methods of contraception (contraception pi[INVESTIGATOR_3353], intrauterine device, bilateral tubal occlusion).
8. To minimize the risk of MRI we will observe [LOCATION_002] Food and Drug Administration (FDA) 
guidelines for magnet strength and exposure to radio waves. We will exclude people with magnetic 
metal in their body through careful review and checklist. Participants will be specifically warned about risks of a pacemaker or metal objects inside the body, as well as the need to remove all metal from their clothing and all metal objects from their pockets. Also, although there are no known risks to 
pregnancy, we will not scan someone who is pregnant, and women in childbearing years will take a pregnancy test just before each MRI scan.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264685] 
become uncomfortable, whether with physical reactions (s uch as elevated blood pressure) or behavior (e.g., 
belligerence) or reported symptoms (reports of psychotic sy mptoms or suicidality). The therapi[INVESTIGATOR_541]'s training will 
be to err on the side of calling the physician unnecessarily rather than allowing the patient's condition to worsen further. While our read of others' experiences wi th similar doses of psilocybin is situations requiring 
medical interventions are highly unlikely, we recognize it is important to be prepared for such an eventuality. I 
have not seen articles documenting the need for rescue medication so can only make the generic suggestion that for difficult psychiatric symptoms, one might fi rst consider a short acting benzodiazepi[INVESTIGATOR_050], such as 
lorazepam, and then an antipsychotic medication, such as quetiapi[INVESTIGATOR_050]. Medical symptoms would be counteracted using appropriate medications, e.g., nifedipi[INVESTIGATOR_220311]. As the half-life of psilocybin and its first metabolite are a few hours it is not surprising that the adverse effects of psilocybin typi[INVESTIGATOR_31228] 1-3 hours, so it is likely that should rescue medication be needed it would only require short acting drugs; adverse events that continue into the next day are re ported as having been mild (e.g., Hasler et al., 1997) 
while the only reported late appearing (i.e., not presen t acutely following psilocybin dose) adverse event is 
mild-moderate headache lasting < 24 hours.
0HWKRGVWR3URWHFW&RQILGHQWLDOLW\
Describe the data management plan and the methods you will employ to protect subject privacy and the confidentiality of research data.  The section should detail how information will be collected, recorded, coded, stored, transmitted, and 
as applicable, shared with other investigators so as to minimize risks related to breach of confidentiality.  Confirm that identifiers are removed, to the extent possible, from research data, and explain if there are links between subject identity 
and research data, or if the data are anonymous.  Also, indica te where the data are stored, who is responsible for data 
safekeepi[INVESTIGATOR_007], and who has access to subject identity and codes, if any, which cross-link research data and subject identity.  Confirm that identifiable data are not collected, stored, or tr ansmitted by [CONTACT_2319], fax, on removable drives, laptops, or via 
the internet without proper protections, e.g. encryption.
Confidentiality will be maintained by [CONTACT_9377][INVESTIGATOR_220312]. Any electronic data,
including laboratory results will be communicated within strict HIPAA rules. Methods by [CONTACT_9444] c onfidentiality 
is protected include HIPAA-compliant videoconferencing and web-based platforms.  Any data sent to the 
company will include initials, gender, marital status, SES and education and date of birth only without additional potential identifying information. Should it become necessary for the treating psychiatrist to contact [CONTACT_423]‚Äôs primary physician to obtain copi[INVESTIGATOR_220313], explicit written agreement for such rec ord transfers will be obtained from the patient. Any 
electronic data stored at the Anxiety Disorders Clinic w ill be kept behind the NYSPI [INVESTIGATOR_220314]. We will be applying for a certificate of confidentiality.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264686] their data stored in this secure centralised database, maintained by [CONTACT_220334] (WCT). Only patients who consent to this process will have their personal data transferred. 
All types of adverse event will be promptly reported to  Compass for use in the Compass/WCT safety database, 
they do however have different recording and reporting requirements, as set out below. For the purposes of reporting to the safety database, and subject to data protection requirements, we will promptly report to Compass all Serious Adverse Events (‚ÄúSAEs‚Äù) regardless of the causal relationship to the 
Study Drug.  
Assessment of Seriousness 
For the purposes of the reporting of the adverse events to Compass, each adverse event will be assessed for 
its seriousness.  An SAE is any event that meets any of the following criteria:
‚Ä¢Death
‚Ä¢Life-threatening
‚Ä¢Inpatient hospi[INVESTIGATOR_1081]
‚Ä¢Persistent or significant disability/incapacity
‚Ä¢Congenital anomaly/birth defect in the offspring of a subject who received the study drug.
Other: Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_11956], 
may be considered an SAE when, based upon appropriate medical judgment, they may jeopardise the Subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events are:
‚Ä¢Intensive treatment in an emergency room or at home for allergic bronchospasm
‚Ä¢Blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_11956]
‚Ä¢Development of drug dependency or drug abuse
Adverse Events of Special Interest 
For the purposes of the safety database, an adverse event of special interest (‚ÄúAESI‚Äù) is an adverse event 
(serious or non-serious) of scientific and medical c oncern specific to the study drug, for which ongoing 
monitoring by [CONTACT_220335]. Su ch adverse events may require further investigation to 
characterise and understand them. 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 31The following events will be reported as AESI:
‚Ä¢Euphoric mood
‚Ä¢Dissociative disorder
‚Ä¢Hallucination
‚Ä¢Psychotic disorder
‚Ä¢Cognitive disorder
‚Ä¢Disturbance in attention
‚Ä¢Mood altered
‚Ä¢Psychomotor skills impaired
‚Ä¢Inappropriate affect
‚Ä¢Overdose
‚Ä¢Intentional product misuse
All AESIs will be followed until resolved or stable.
Reporting Adverse Events Each adverse event will be assessed to determine whether it should be classified as a SAE.  If the adverse 
event is considered serious, we will report this event in  line with requirements of the study sponsor and the 
IRB. This may include completing a sponsor specific SAE reporting form, within [ADDRESS_264687] becoming aware of 
such adverse event. These events will be reported and transferred on our Institution‚Äôs own study CRFs. 
All information about adverse events will be collected and once the relevant form is completed, it will be 
scanned and sent by [CONTACT_220336]. The initial report should include the following 
information:
‚Ä¢E v e n t
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 32‚Ä¢ Study code
‚Ä¢ Reporter name [CONTACT_3669] [CONTACT_220337]: 
[EMAIL_2828]
In cases where the email system is unavailable, site staff will send the SAE by [CONTACT_12100]: +[PHONE_4673] (US) and +44 [PHONE_4674] (ROW).
Category of Adverse Event Time Frame to Report to 
Compass/WCT Database How to Report to 
Compass/WCT Database 
Adverse Event (AE) Timely Manner/ Before the 
end of the studySubmit site specific AE CRF to 
WCT
Serious Adverse Event (SAE) Within [ADDRESS_264688] (AESI)Within [ADDRESS_264689] been colle cted formally for the Study Drug, all SAEs that are 
considered to be related will also be unexpected and therefore classified as Serious, Unexpected, Suspected Adverse Reactions (S[LOCATION_003]Rs). Classification of an SAE as a S[LOCATION_003]R will be determined on a case by [CONTACT_220338]. Once an unexpected event has occurred, it will become expected in the future. The IBD will be updated annually to reflect changes in expected adverse events.  
GDPRAs owners of the external safety database, Compass Pathways are the ‚Äúdata controller‚Äù for this aspect of the 
research. WCT and the research team will act as ‚Äúdata processors‚Äù.  
Subjects will have the following rights regarding accessing their data stored in this database: 
1. To request to review their data held in the safety database.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/[ADDRESS_264690]; they will work with us to resolve them as needed.
'LUHFW%HQHILWVWR6XEMHFWV
Describe only benefits to individual subjects that are likely  to accrue during the study itself. Do not include subject 
compensation or treatment to be provided at the end of the study, as these do not figure into the IRB's risk/benefit considerations.  Do not describe diagnostic and evaluation components unless subjects receive clinical feedback. Do not describe the anticipated scientific benefits of the resear ch.  Some studies offer no direct benefit to subjects.
There may be no direct benefit.  The information we get from this study may help us treat people with BDD 
better in the future
&RPSHQVDWLRQDQGRU5HLPEXUVHPHQW
If compensation or reimbursement for expenses will be offered to subjects, please describe and indicate total amount and schedule of payment(s). If transportation is reimbursed, state if receipts are necessary for reimbursement.  Include justification for compensation amounts and indicate if there are bonus payments.
 $[ADDRESS_264691] dosing visit ($100 each visit).$250 after completion after completion of 5 follow up visits. ($50 each visit)Total compensation will be $550
3URWRFRO6SHFLILF3ODQV363V
All federally funded, more than minimal risk studies are required to include a Training Plan, an Internal 
Monitoring/Quality Assurancee Plan, and a Data Management Plan. Collectively, these plans are called the Protocol Specific Plans or PSPs. More information can be found on the IRB  website (irb.nyspi.org) regarding these plans and should be reviewed prior to submission. 
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 347UDLQLQJ3ODQV
A training plan should describe, in detail, ALL training required for each member of the study team, frequency of 
the training, and location of the Training Log and training  certificates. Elements of an effective training plan 
include: all sessions documented with an attendance list, all members of the study team listed on the Delegation of Authority log must be in compliance with the training  plan and be trained for each study procedure they are 
authorized to perform, the training log is maintained by [CONTACT_220339], and sample timepoints for the Training Log are before protocol initiation meeting, protocol initiation meeting, annual protocol meeting, and new staff training.   The st udy is in data analysis and is not currently enrolling or 
recruiting participant so this would not be applicable to us.
,QWHUQDO0RQLWRULQJ4XDOLW\$VVXUDQFH3ODQ
Please utilize the Quality Assurance Monitoring plan template on the NYSPI [INVESTIGATOR_220315] (irb.nyspi.org) and cut & paste to this section. A lead QA monitor will need to be  designated and named in the study‚Äôs monitoring plan. 
Section A will describe the monitoring schedule and repor ting. Section B will describe the data that will be 
reviewed on an ongoing basis.  The study is in data analysis and is not currently enrolling or recruiting participant so this would not be applicable to us.
'DWD0DQDJHPHQW3ODQ
The required elements of the Data Management Plan include: identification of the database platform (e.g., REDCap) and inclusion of an attestation that it is Part 11 compliant, identification of a qualified staff member who designs and maintains the database, design and implementation of data system training for all Principal Investigators & research coordinators & all protocol staff, and significant changes to the data management plan will be submitted as protocol amendments in PRISM.  The study is in data analysis and is not currently enrolling or recruiting participant so this would not be applicable to us.
5HIHUHQFHV
Please limit references, preferably no more than twenty.
Buhlmann U, Glaesmer H, Mewes R, Fama JM, Wilhelm S, Br√§hler E, et al. Updates on the prevalence of body 
dysmorphic disorder: a population-based survey. Psychiatry Res. 2010 Jun 30;178(1):171‚Äì5.
Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatmentresistant
depression: an open-label feasibility study. Lancet. 2016;3(7):619-627.
Dakwar E. The death and rebirth of hallucinogens. Drug and Alcohol Dependence. 2016;165:293‚Äì297.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 35Feusner JD, Moller H, Altstein L, et al. Inverted  face processing in body dysmorphic disorder. J Psychiatr Res . 
2010;44(15):1088‚Äì1094. 
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al. 1999b. Psychopathological, neuroendocrine and
autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and D-methamphetamine inhealthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology(Berl). 1999b;142(1):41-50.
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, et al. 1999b. Psychopathological, neuroendocrine and
autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and D-methamphetamine inhealthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology(Berl). 1999b;142(1):41-50.
Griffiths RR, Johnson MW, Richards WA, Richards  BD, McCann U, Jesse R. Psilocybin occasioned
mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl).2011;218(4):649-665.
Hanes, K. R. Serotonin, Psilocybin, and Body Dysmorphic Disorder. J. Clin. Psychopharmacol. (1996) 16:188-
189.
Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects
of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology(Berl). 2004;172(2):145-156.
Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, et al. Clomipramine vs Desipramine 
Crossover Trial in Body Dysmorphic Disorder: Selective Efficacy of a Serotonin Reuptake Inhibitor in Imagined Ugliness. Arch Gen Psychiatry. 1999 Nov 1;56(11):1033‚Äì9.
Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability, and efficacy of
psilocybin in 9 patients with obsessive-compulsive disorder. J. Clin. Psychiatry (2006).
doi:10.4088/JCP.v67n1110
Nichols DE: Psychedelics. Psychopharm Rev 2016;68:264-355.Oosthuizen P, Lambert T, Castle DJ: Dysmorphic concern: Prevalence and association with clinical variables. 
Australian and New Zealand Journal of Psychiatry 1998; 32:129-132
Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. Oxford University 
Press; 2005. 412 p.
Protocol Summary Form             
Rev. 10 ‚Äì 11/08/2022 36Phillips KA, Albertini RS, Rasmussen SA. A Randomized Placebo-Controlled Trial of Fluoxetine in Body 
Dysmorphic Disorder. Arch Gen Psychiatry. 2002 Apr 1;59(4):381‚Äì8.
Phillips KA, Keshavian A, Dougherty DD, Stout RL, Menard W, Wilhelm S. Pharmacotherapy Relapse Prevention 
in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2016 Sep 1;173(9):887‚Äì95.
Phillips KA, Menard W, Pagano ME, Fay C, Stout RL. Delusional versus nondelusional body dysmorphic 
disorder: clinical features and course of illness.  J Psychiatr Res. 2006 Mar;40(2):95-104.
Ralph-Nearman C, Arevian AC, Puhl M, et al. A Nove l Mobile Tool (Somatomap) to Assess Body Image 
Perception Pi[INVESTIGATOR_220316]: Cross-Sectional Study. JMIR Ment Health . 
2019;6(10):e14115. Published [ADDRESS_264692] 29.
Studerus E, Kometer M, Hasler F Vollenweider FX: Acut e, subacute and long-term subjective effects of
psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharm 2011;25(11):1434‚Äì52.
Wilhelm S, Phillips KA, Didie E, Buhlmann U, Greenberg JL, Fama JM, et al. Modular cognitive-behavioral 
therapy for body dysmorphic disorder: a randomized controlled trial. Behav Ther. 2014 May;45(3):314‚Äì27.
  
Statistical Anal ysis Plan  
The primary efficacy  measure was BDD symptom severity, as measured by [CONTACT_220340] -
YBOCS , a clinician -rated scale  (total score range:  0-48, with higher scores indicating 
greater severity) . Response to treatment has been  defined and validat ed as > 30% 
decrease in total score, and partial -to-full remission  as total score <16 (Fernandez de la 
Cruz et al. 2019 ).  
 
Statistical Ana lyses:  For YBOCS and other repeated outcome  measures, repeat ed 
measures ANOVA s with Greenhouse -Geiser corrections will be  conducted a cross time 
points  from baseline to week 12  using SPSS  Version 23.0 (IBM SPSS Statistics for 
Windows, Version 23.0. Armonk, NY: IBM Corp ), with post hoc pairwise Bonferroni -
corrected comparison s. For the HRSD a  paired  samples t-test w ill be performed  to 
compare baseline to week 12 scores . 
 